XML 26 R12.htm IDEA: XBRL DOCUMENT

Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders

9 Months Ended

Sep. 30, 2021

Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders

Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders

Note 5. Income per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders

Basic net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders is calculated based upon the weighted-average number of shares outstanding during the period. Diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders gives effect to all potential dilutive shares outstanding during the period, such as stock options, non-vested restricted stock units and shares issuable under the Company’s Employee Stock Purchase Plan, or ESPP.

For the three and nine months ended September 30, 2021, options to purchase 1,885,093 and 2,045,878 shares of stock, respectively, with a weighted-average exercise price of $20.86 per share and $20.74 per share, respectively, were excluded from the computation of diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders because the effect would be anti-dilutive.

For the three and nine months ended September 30, 2020, options to purchase 1,271,347 and 1,928,629 shares of stock, respectively, with a weighted-average exercise price of $21.35 per share and $20.84 per share, respectively, and the reallocation of net income attributable to non-controlling interests were excluded in the computation of diluted net income per common share attributable to Amphastar Pharmaceuticals, Inc. stockholders because the effect would be anti-dilutive.

The following table provides the calculation of basic and diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders for each of the periods presented:


		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2021			2020			2021			2020

		(in thousands, except per share data)
Basic and dilutive numerator:
Net income attributable to Amphastar Pharmaceuticals, Inc.		$	29,548		$	3,919		$	42,356		$	7,676
Denominator:
Weighted-average shares outstanding — basic			48,022			47,496			47,758			46,886

Net effect of dilutive securities:
Incremental shares from equity awards			1,987			2,352			1,935			2,036
Weighted-average shares outstanding — diluted			50,009			49,848			49,693			48,922
Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — basic		$	0.62		$	0.08		$	0.89		$	0.16
Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — diluted		$	0.59		$	0.08		$	0.85		$	0.16